leadf
logo-loader
viewANGLE PLC

ANGLE completes FDA submission for Parsortix system for metastatic breast cancer

ANGLE PLC's (LON:AGL, OTCQX:ANPCY) Andrew Newland talks to Proactive's Katie Pilbeam after announcing the completion of their submission to the FDA for its Parsortix PC1 liquid biopsy for use in women with metastatic breast cancer (MBC).

Newland calls the announcement 'a massive day' after five years' work, including over 400 technical reports and documents and the results from 15,000 samples, have now been submitted to the FDA.

He goes on to explain that the process could take six months to complete but alludes to similar companies who have completed a similar trajectory who 'have achieved investor valuations of multiple billions of dollars' as a consequence.

Quick facts: ANGLE PLC

Price: 43.5 GBX

AIM:AGL
Market: AIM
Market Cap: £93.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read